Affinia Therapeutics: Funding, Investors & Team (Sep 2026)
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.
Affinia Therapeutics has raised $150M across 2 funding rounds on record, the most recent a Series C of $40.0M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Affinia Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Affinia Therapeutics Funding Rounds
Affinia Therapeutics raised $110M in an undisclosed round announced in May 2021.
4.4 years later, a Series C of $40.0M was announced in Oct 2025.
Affinia Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Affinia Therapeutics Funding Compared to Other Biotechnology Startups
Affinia Therapeutics' latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Affinia Therapeutics in Biotechnology and Waltham
Companies Similar to Affinia Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Affinia Therapeutics Funding FAQs
What does Affinia Therapeutics do?
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.
How much funding has Affinia Therapeutics raised?
Affinia Therapeutics has raised $150M across 2 rounds on record. The most recent is a Series C of $40.0M announced in Oct 2025.
When did Affinia Therapeutics last raise funding?
Affinia Therapeutics' most recent funding round on record is a Series C of $40.0M, announced in Oct 2025.
Who founded Affinia Therapeutics?
FundedIQ lists Rob Aboud (Founder) at Affinia Therapeutics.
Who is the CEO of Affinia Therapeutics?
Rick M. is listed as CEO at Affinia Therapeutics.
Where is Affinia Therapeutics headquartered?
Affinia Therapeutics is based in Waltham, Massachusetts, United States.
How many employees does Affinia Therapeutics have?
Affinia Therapeutics is in the 51-100 employee band.
How does Affinia Therapeutics' funding compare to other Biotechnology startups?
Affinia Therapeutics' latest round of $40.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Affinia Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Affinia Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.